Relationship between disease awareness and severity of kidney disease in autosomal dominant polycystic kidney disease patients.
autosomal dominant polycystic kidney disease
chronic kidney disease
dialysis
disease awareness
Journal
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
ISSN: 1744-9987
Titre abrégé: Ther Apher Dial
Pays: Australia
ID NLM: 101181252
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
revised:
19
04
2022
received:
05
01
2022
accepted:
24
04
2022
pubmed:
27
4
2022
medline:
5
1
2023
entrez:
26
4
2022
Statut:
ppublish
Résumé
Polycystic kidney disease (PKD) is responsible for 5%-10% of end-stage renal disease. We examined the relationship between renal and extrarenal findings, disease severity, and the level of consciousness of PKD patients. Patients were asked to answer the questionnaire about PKD. Disease severity was determined according to estimated glomerular filtration rate, and disease awareness was assessed by adapting the Disease Perception Scale to PKD. Awareness of patients was evaluated comparatively with chronic kidney disease stage, age, region, and symptoms. One out of five patients does not know that this disease is inherited. Mean awareness scores of the patients decreased significantly with increasing age. Awareness scores were significantly higher in patients with flank pain, hematuria, and urinary tract stones. Although PKD is the most common hereditary kidney disease, the rate of patients' knowledge on this subject is low. Increased awareness might lead to better treatment in those patients.
Identifiants
pubmed: 35470962
doi: 10.1111/1744-9987.13860
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
117-122Informations de copyright
© 2022 International Society for Apheresis and Japanese Society for Apheresis.
Références
Levy M, Feingold J. Estimating prevalence in single-gene kidney diseases progressing to renal failure. Kidney Int. 2000;58(3):925-43.
Gabow PA. Autosomal dominant polycystic kidney disease. N Engl J Med. 1993;329(5):332-42.
Soroka S, Alam A, Beavilacqua M, Girard LP, Komenda P, Loertscher R, et al. Assessing risk of disease progression and pharmacological management of autosomal dominant polycystic kidney disease: a Canadian Expert Consensus. Can J Kidney Health Dis. 2017;4:1-12.
Torres VE, Bankir L, Grantham JJ. A case for water in the treatment of polycystic kidney disease. Clin J Am Soc Nephrol. 2009;4(6):1140-50.
Seyahi N, Ateş K, Süleymanlar G. Current status of renal replacement therapy in Turkey: a summary of the 2019 Turkish Society of Nephrology registry report. Turk J Nephrol. 2021;30(2):105-11.
Harris PC, Torres VE. Autosomal dominant polycystic kidney disease. Gene Clinics Online Reviews at Gene Tests-Gene Clinics (University of Washington, Seattle, 2002). In: GeneReviews® [Internet]. Seattle, WA: University of Washington, Seattle; 1993-2021 [2002 Jan 10].
Hateboer N, Dijk MA, Bogdanova N, et al. Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet. 1999;353(9147):103-7.
Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007;369(9569):1287-301.
Chapman AB, Bost JE, Torres VE, Guay-Woodford L, Bae KT, Landsittel D, et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2012;7(3):479-6.
Drug Approval Package: Jynarque (tolvaptan) Otsuka Pharmaceutical Development & Commercialization, Inc. application Number: 204441, Approval Date: 04/23/2018 [cited 2021 Dec 20]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/204441Orig1s000TOC.cfm
Pei Y, Obaji J, Dupuis A, Paterson AD, Magistroni R, Dicks E, et al. Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol. 2009;20(1):205-12.
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-12.
Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;3(Suppl 3):1-150.
Weinman J, Petrie KJ, Moss-Morris R, Horne R. The illness perception questionnaire: a new method for assessing the cognitive representation of illness. Psychol Health. 1996;11:431-45.
Grantham JJ. Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med. 2008;359(14):1477-85.
Fick GM, Gabow PA. Hereditary and acquired cystic disease of the kidney. Kidney Int. 1994;46(4):951-64.
Chauveau D, Pirson Y, Verellen-Dumoulin C, Macnicol A, Gonzalo A, Grünfeld JP. Intracranial aneurysms in autosomal dominant polycystic kidney disease. Kidney Int. 1994;45(4):1140-6.
Tan AY, Blumenfeld J, Michaeel A, Donahue S, Bobb W, Parker T, et al. Autosomal dominant polycystic kidney disease caused by somatic and germline mosaicism. Clin Genet. 2015;87(4):373-7.
Bell PE, Hossack KF, Gabow PA, Durr JA, Johnson AM, Schrier RW. Hypertension in autosomal dominant polycystic kidney disease. Kidney Int. 1988;34(5):683-90.
Chapman AB, Johnson A, Gabow PA, Schrier RW. The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med. 1990;323(16):1091-6.
Clark LA, Whitmire S, Patton S, Clark C, Blanchette CM, Howden R. Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease. J Med Econ. 2017;20(7):715-22.
Patch C, Charlton J, Roderick PJ, Gulliford MC. Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: a population-based study. Am J Kidney Dis. 2011;57(6):856-62.
Eroglu E, Kocyigit I, Cetin M, Zararsiz G, Imamoglu H, Bayramov R, et al. Multiple urinary tract infections are associated with genotype and phenotype in adult polycystic kidney disease. Clinical and experimental nephrology. 2019;23(10):1188-95.